Treatment for Blunt Cerebrovascular Injuries: Equivalence of Anticoagulation and Antiplatelet Agents | Traumatic Brain Injury | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Cothren  CCMoore  EEBiffl  WL  et al.  Anticoagulation is the gold standard therapy for blunt carotid injuries to reduce stroke rate.  Arch Surg 2004;139 (5) 540- 546PubMedGoogle ScholarCrossref
Biffl  WLMoore  EEOffner  PJBrega  KEFranciose  RJBurch  JM Blunt carotid arterial injuries: implications of a new grading scale.  J Trauma 1999;47 (5) 845- 853PubMedGoogle ScholarCrossref
Biffl  WLRay  CE  JrMoore  EE  et al.  Treatment-related outcomes from blunt cerebrovascular injuries: importance of routine follow-up arteriography.  Ann Surg 2002;235 (5) 699- 707PubMedGoogle ScholarCrossref
Fabian  TCPatton  JH  JrCroce  MAMinard  GKudsk  KAPritchard  FE Blunt carotid injury: importance of early diagnosis and anticoagulant therapy.  Ann Surg 1996;223 (5) 513- 525PubMedGoogle ScholarCrossref
Miller  PRFabian  TCBee  TK  et al.  Blunt cerebrovascular injuries: diagnosis and treatment.  J Trauma 2001;51 (2) 279- 286PubMedGoogle ScholarCrossref
Biffl  WLMoore  EERyu  RK  et al.  The unrecognized epidemic of blunt carotid arterial injuries: early diagnosis improves neurologic outcome.  Ann Surg 1998;228 (4) 462- 470PubMedGoogle ScholarCrossref
Cothren  CCMoore  EERay  CE  Jr  et al.  Screening for blunt cerebrovascular injuries is cost effective  Am J Surg 2005;190 (6) 845- 849PubMedGoogle Scholar
Miller  PRFabian  TCCroce  MA  et al.  Prospective screening for blunt cerebrovascular injuries: analysis of diagnostic modalities and outcomes.  Ann Surg 2002;236 (3) 386- 395PubMedGoogle ScholarCrossref
Cogbill  THMoore  EEMeissner  M  et al.  The spectrum of blunt injury to the carotid artery: a multicenter perspective.  J Trauma 1994;37 (3) 473- 479PubMedGoogle ScholarCrossref
Davis  JWHolbrook  TLHoyt  DBMackersie  RCField  TO  JrShackford  SR Blunt carotid artery dissection: incidence, associated injuries, screening, and treatment.  J Trauma 1990;30 (12) 1514- 1517PubMedGoogle ScholarCrossref
Fabian  TCGeorge  SM  JrCroce  MAMangiante  ECVoeller  GRKudsk  KA Carotid artery trauma: management based on mechanism of injury.  J Trauma 1990;30 (8) 953- 963PubMedGoogle ScholarCrossref
Wahl  WLBrandt  MMThompson  BGTaheri  PAGreenfield  LJ Antiplatelet therapy: an alternative to heparin for blunt carotid injury.  J Trauma 2002;52 (5) 896- 901PubMedGoogle ScholarCrossref
Edwards  NMFabian  TCClaridge  JATimmons  SDFischer  PECroce  MA Antithrombotic therapy and endovascular stents are effective treatment for blunt carotid injuries: results from long-term followup.  J Am Coll Surg 2007;204 (5) 1007- 1015PubMedGoogle ScholarCrossref
Eachempati  SRVaslef  SNSebastian  MWReed  RL  II Blunt vascular injuries of the head and neck: is heparinization necessary?  J Trauma 1998;45 (6) 997- 1004PubMedGoogle ScholarCrossref
Carrillo  EHOsborne  DLSpain  DAMiller  FBSenler  SORichardson  JD Blunt carotid artery injuries: difficulties with the diagnosis prior to neurologic event.  J Trauma 1999;46 (6) 1120- 1125PubMedGoogle ScholarCrossref
Cothren  CCMoore  EERay  CE  JrJohnson  JLMoore  JBBurch  JM Cervical spine fracture patterns mandating screening to rule out blunt cerebrovascular injury.  Surgery 2007;141 (1) 76- 82PubMedGoogle ScholarCrossref
Utter  GHHollingworth  WHallam  DKJarvik  JGJurkovich  GJ Sixteen-slice CT angiography in patients with suspected blunt carotid and vertebral artery injuries.  J Am Coll Surg 2006;203 (6) 838- 848Google ScholarCrossref
Cothren  CCMoore  EERay  CE  Jr  et al.  Carotid artery stents for blunt cerebrovascular injury: risks exceed benefits.  Arch Surg 2005;140 (5) 480- 486PubMedGoogle ScholarCrossref
Mayberry  JCBrown  CVMullins  RJVelmahos  GC Blunt carotid artery injury: the futility of aggressive screening and diagnosis.  Arch Surg 2004;139 (6) 609- 613PubMedGoogle ScholarCrossref
Hébert  PCWells  GBlajchman  MA  et al. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group, A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care [published correction appears in N Engl J Med. 1999;340(13):1056].  N Engl J Med 1999;340 (6) 409- 417PubMedGoogle ScholarCrossref
July 20, 2009

Treatment for Blunt Cerebrovascular Injuries: Equivalence of Anticoagulation and Antiplatelet Agents

Author Affiliations

Author Affiliations: Department of Surgery, Denver Health Medical Center and University of Colorado School of Medicine, Denver.

Arch Surg. 2009;144(7):685-690. doi:10.1001/archsurg.2009.111

Hypothesis  We hypothesize that the 2 antithrombotic treatment regimens, systemic heparin sodium vs antiplatelet agents, are equivalent for the treatment of blunt cerebrovascular injuries (BCVIs) to prevent devastating injury-related strokes.

Design  Retrospective review of a prospective database.

Setting  Level I trauma center.

Patients  Patients with BCVIs from January 1, 1997, to January 1, 2007.

Main Outcome Measures  Incidence of cerebrovascular accident (CVA), stratified by treatment.

Results  During the study period, 422 BCVIs were identified in 301 patients (64.8% men; mean [SEM] age, 37.0 [0.8] years; mean [SEM] injury severity score, 27.0 [0.9]). A total of 22 patients presented with neurologic ischemia, and 5 patients sustained CVAs after embolization and/or stenting of an injury. Treatment was initiated for 282 asymptomatic BCVIs (heparin, 192; aspirin, 67; aspirin and/or clopidogrel, 23); 1 patient had a CVA (0.5%). Of 107 patients with untreated, asymptomatic BCVIs, 23 (21.5%) had a CVA. For untreated patients sustaining BCVI-related CVAs, the mean (SEM) time to diagnosis was 58 (10) hours. For those who did not exhibit symptoms within 2 hours of injury, mean time to diagnosis of CVA was 75 (11) hours. Injury healing rates (heparin, 39%; aspirin, 43%; aspirin/clopidogrel, 46%) and injury progression rates (12%; 10%; 15%) were equivalent between therapeutic regimens.

Conclusions  With an overall CVA risk of 21% and a documented latent period, comprehensive screening, early diagnosis, and institution of antithrombotic therapy for BCVI are clearly warranted. The type of treatment, heparin vs antiplatelet agents, does not appear to affect either stroke risk or injury healing rates.